Daily non-political popular news in brief.
MERLIN TIMI-36 study provides new safety & efficacy data for unique anti-anginal therapy
03-27-2007 · EurekAlert!Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
Read more »
Keywords: merlin, timi-36, study, provides, safety, efficacy, data, unique, anti-anginal, therapy, timi, provide, anti, anginal
« Previous | Next »
Similar news on "MERLIN TIMI-36 study provides new safety & efficacy data for unique anti-anginal therapy":
- MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
03-27-2007 · EurekAlert!
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
Similar news · Read more »
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
11-13-2006 · EurekAlert!
Amgen (NASDAQ: AMGN) announced Enbrel (R) (etanercept) is the first biologic with published data to show sustained improvements in multiple efficacy measures in rheumatoid arthritis patients completing up to nine years of therapy. Current data suggest Enbrel is both effective and safe in long-term RA use, and the new data, presented at the American College of Rheumatology scientific meeting, provide a degree of reassurance that unexpected safety concerns do not appear to develop after nine years of use.
Similar news · Read more »
- Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years
11-13-2006 · EurekAlert!
Amgen (NASDAQ: AMGN) announced patients with ankylosing spondylitis who received treatment with Enbrel (R) (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy, according to data from an ongoing open-label, multinational, phase 4 extension study presented at the American College of Rheumatology scientific meeting. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks.
Similar news · Read more »
- New Analyses of long-term LIALDA (mesalamine) data presented at ACG
10-15-2007 · EurekAlert!
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at the American College of Gastroenterology meeting in Philadelphia.
Similar news · Read more »
- Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder
05-22-2007 · EurekAlert!
A study presented today at the 160th Annual Meeting of the American Psychiatric Association showed that, in adults with major depressive disorder, adding ABILIFY(R)(aripiprazole) to antidepressant therapy resulted in significant improvement in the primary endpoint, the MADRS Total Score. A reduction in MADRS Total Score represents improvement in depressive symptoms.
Similar news · Read more »
- Clinical study results using Aldagen's product to isolate cord blood stem cells presented at ASH
12-11-2006 · EurekAlert!
Interim data from a clinical trial using Aldagen's product, ALDESORT® to isolate stem cells from cord blood was presented at the 48th Annual Meeting of the American Society of Hematology demonstrating improved safety and efficacy when using ALDESORT compared to the COBLT control group. The trial is being conducted by Joanne Kurtzberg, MD, the Duke University physician who pioneered the use of umbilical cord blood as treatment for fatal childhood cancers and genetic diseases.
Similar news · Read more »
- Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
10-24-2007 · EurekAlert!
Data presented today at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians, demonstrate concomitant use of nebulized formoterol fumarate and tiotropium provided improved bronchodilation over tiotropium monotherapy and was well-tolerated in this clinical study.
Similar news · Read more »
- Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis
06-13-2007 · EurekAlert!
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced the presentation of additional data that showed that the safety profile of Enbrel was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis who completed up to eight years of therapy. The study results will be presented at the European League Against Rheumatism Annual Congress, an international rheumatology meeting, in Barcelona, Spain.
Similar news · Read more »
- Novel platelet therapy may reduce PCI complications
03-24-2007 · EurekAlert!
Despite the availability of numerous antithrombotic therapies, adverse events following percutaneous coronary intervention such as late-stent thrombosis are still a concern for cardiologists, and there's a need for medications that can minimize the risk of these complications but also manage the rate of bleeding. A study presented today at the American College of Cardiology's Innovation in Intervention: i2 Summit evaluates the safety and efficacy of a novel oral thrombin receptor antagonist in reducing PCI complications.
Similar news · Read more »
- Combination HDL/LDL therapy has no effect on plaque build-up
03-26-2007 · EurekAlert!
Two RADIANCE studies presented today at the American College of Cardiology's 56th Annual Scientific Session assessed the effects of adding torcetrapib to atorvastatin among patients to improve their cholesterol levels. Although the ILLUMINATE study and other trials involving torcetrapib were recently stopped because of safety concerns, the effect of the drug on carotid intima-media thickness (CIMT) may provide useful information on whether it slows the progression of atherosclerosis.
Similar news · Read more »
